NCT02877303
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 50 versions: 19 with changes below, 31 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028
- Eligibility criteria expanded, about 15 words
- Publications: details revised at 4 of 4 entries
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary and study completion dates: Nov 1, 2023 to Nov 1, 2026v35
- Notable Eligibility criteria shortened, about 7 wordsv29
Show 13 earlier versionsHide 13 earlier versions
- Notable Primary and study completion dates: Nov 1, 2021 to Nov 1, 2023v26
Minor Enrollment target: 60 to 80v24 Show 4 more changesShow less
- Interventions: Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Laboratory… to Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Inotuzumab…
- Study description expanded, about 30 words
- Site contact updated
- Study title expanded, about 2 words
- Notable Primary and study completion dates: Nov 1, 2020 to Nov 1, 2021v22
Notable Primary endpoint revisedv18 Show 9 more changesShow less
- Eligibility criteria expanded, about 2 words
- Primary completion date: Nov 2020 to Nov 1, 2020
- Study completion date: Nov 2021 to Nov 1, 2020
- Interventions: 6-Mercaptopurine (Drug), Blinatumomab (Drug), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin (Drug), G-CSF… to Blinatumomab (Biological), Cyclophosphamide (Drug), Cytarabine (Drug), Dexamethasone (Drug), Doxorubicin Hydrochloride (Drug), Laboratory…
- Secondary endpoints expanded, about 14 words
- Study description expanded, about 427 words
- Study site revised
- Collaborator revised
- Study title shortened, about 3 words
- Minor Study completion date: Nov 2020 to Nov 2021v17
- Minor Study description shortened, about 1,411 wordsv15
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 20 to 60
- Study description revised
- Site details revised
- Notable Eligibility criteria shortened, about 56 words
- Study description expanded, about 169 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 60 to confirmed 20
- Start date: Nov 2016 to Nov 1, 2016
- Site details revised
- Notable Eligibility criteria expanded, about 120 words
- Study description expanded, about 51 words
- Minor Study completion date: Nov 2020
- Study description expanded, about 137 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study description shortened, about 66 words
- Site details revised
- Notable Eligibility criteria expanded, about 48 words
- Study description shortened, about 7 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Relapse-free survival (RFS)
Timeframe: From date of treatment start until the date of death or disease relapse, assessed for up to 24 months
Secondary (4)
Overall survival
Overall response rate
Minimal residual disease negativity rate
Incidence of adverse events
Arms and interventions
Treatment (blinatumomab, inotuzumab, combination chemotherapy)Experimental
See detailed description.
Biologicals: Blinatumomab, Inotuzumab Ozogamicin, Ofatumumab, Rituximab
Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Prednisone, Vincristine Sulfate
Other: Laboratory Biomarker Analysis
Sites
1 site in 1 country
- M D Anderson Cancer CenterHouston, Texas, United States